Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Apitegromab

Stage Phase 2Stale

Sponsor Scholar Rock, Inc

Route injection

Class Myostatin/activin

Mechanism anti-proMyostatin monoclonal antibody

Sources

registry, as of 2026-01-23Stale

https://clinicaltrials.gov/study/NCT06445075

Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese. Overall status COMPLETED. Phases PHASE2. Lead sponsor Scholar Rock, Inc.. Enrollment 102. Conditions Overweight and Obesity. A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 receptor agonist therapy in subjects with overweight or obesity

ClinicalTrials.gov NCT06445075 protocol and results modules

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT06445075

during the treatment period. Apitegromab Apitegromab (SRK-015) is a fully human anti-proMyostatin monoclonal antibody (mAb) that specifically binds to human pro/latent myostatin, inhibiting myostatin activation. Apitegromab was administered every 4 weeks by intravenous (IV) infusion. Placebo Same

NCT06445075 description or intervention text

Studies

EMBRAZE

Registry NCT06445075

Phase Phase 2

Status Completed

Enrollment 102

Start 2024-05-21

Primary completion 2025-03-04

Study completion 2025-06-17

Catalyst Primary completion. 2025-03-04. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Cohort 1

Regimen every 4 weeks

Weeks 4

Comparator placebo

Population Overweight and Obesity

Cohort 2

Regimen every 4 weeks

Weeks 4

Population Overweight and Obesity